Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants.
Omicron variant
RT-qPCR
SARS-CoV-2
variant screening
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
received:
09
01
2022
revised:
01
03
2022
accepted:
12
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
2
4
2022
Statut:
epublish
Résumé
The recently emerged SARS-CoV-2 B.1.1.529 lineage and its sublineages (Omicron variant) pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available monoclonal antibody therapies. RT-PCR-based variant tests can be used to screen large sample-sets rapidly and accurately for relevant variants of concern (VOC). The aim of this study was to establish and validate a multiplex assay on the cobas 6800/8800 systems to allow discrimination between the two currently circulating VOCs, Omicron and Delta, in clinical samples. Primers and probes were evaluated for multiplex compatibility. Analytic performance was assessed using cell culture supernatant of an Omicron variant isolate and a clinical Delta variant sample, normalized to WHO-Standard. Clinical performance of the multiplex assay was benchmarked against NGS results. In silico testing of all oligos showed no interactions with a high risk of primer-dimer formation or amplification of human DNA/RNA. Over 99.9% of all currently available Omicron variant sequences are a perfect match for at least one of the three Omicron targets included in the multiplex. Analytic sensitivity was determined as 19.0 IU/mL (CI95%: 12.9-132.2 IU/mL) for the A67V + del-HV69-70 target, 193.9 IU/mL (CI95%: 144.7-334.7 IU/mL) for the E484A target, 35.5 IU/mL (CI95%: 23.3-158.0 IU/mL) for the N679K + P681H target and 105.0 IU/mL (CI95%: 80.7-129.3 IU/mL) for the P681R target. All sequence variances were correctly detected in the clinical sample set (225/225 Targets). RT-PCR-based variant screening compared to whole genome sequencing is both rapid and reliable in detecting relevant sequence variations in SARS-CoV-2 positive samples to exclude or verify relevant VOCs. This allows short-term decision-making, e.g., for patient treatment or public health measures.
Sections du résumé
BACKGROUND
The recently emerged SARS-CoV-2 B.1.1.529 lineage and its sublineages (Omicron variant) pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available monoclonal antibody therapies. RT-PCR-based variant tests can be used to screen large sample-sets rapidly and accurately for relevant variants of concern (VOC). The aim of this study was to establish and validate a multiplex assay on the cobas 6800/8800 systems to allow discrimination between the two currently circulating VOCs, Omicron and Delta, in clinical samples.
METHODS
Primers and probes were evaluated for multiplex compatibility. Analytic performance was assessed using cell culture supernatant of an Omicron variant isolate and a clinical Delta variant sample, normalized to WHO-Standard. Clinical performance of the multiplex assay was benchmarked against NGS results.
RESULTS
In silico testing of all oligos showed no interactions with a high risk of primer-dimer formation or amplification of human DNA/RNA. Over 99.9% of all currently available Omicron variant sequences are a perfect match for at least one of the three Omicron targets included in the multiplex. Analytic sensitivity was determined as 19.0 IU/mL (CI95%: 12.9-132.2 IU/mL) for the A67V + del-HV69-70 target, 193.9 IU/mL (CI95%: 144.7-334.7 IU/mL) for the E484A target, 35.5 IU/mL (CI95%: 23.3-158.0 IU/mL) for the N679K + P681H target and 105.0 IU/mL (CI95%: 80.7-129.3 IU/mL) for the P681R target. All sequence variances were correctly detected in the clinical sample set (225/225 Targets).
CONCLUSION
RT-PCR-based variant screening compared to whole genome sequencing is both rapid and reliable in detecting relevant sequence variations in SARS-CoV-2 positive samples to exclude or verify relevant VOCs. This allows short-term decision-making, e.g., for patient treatment or public health measures.
Identifiants
pubmed: 35337015
pii: v14030608
doi: 10.3390/v14030608
pmc: PMC8950896
pii:
doi:
Substances chimiques
DNA Primers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Chem Biol. 2001 Jan;8(1):1-7
pubmed: 11182314
Sci Rep. 2021 Oct 14;11(1):20494
pubmed: 34650153
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Mar 3;:
pubmed: 35240676
Viruses. 2021 Apr 12;13(4):
pubmed: 33921216
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Science. 2021 Mar 12;371(6534):1139-1142
pubmed: 33536258
J Med Virol. 2022 Apr;94(4):1255-1256
pubmed: 34850421
PLoS Biol. 2021 May 7;19(5):e3001236
pubmed: 33961632
Virus Evol. 2020 Oct 05;6(2):veaa075
pubmed: 33318859
Nucleic Acids Res. 2006 May 02;34(8):e60
pubmed: 16670427
Science. 2022 Mar 15;:eabn4947
pubmed: 35289632
J Mol Diagn. 2020 Dec;22(12):1367-1372
pubmed: 32961315
J Med Virol. 2022 May;94(5):1784-1786
pubmed: 34964500
Nat Med. 2022 Mar;28(3):490-495
pubmed: 35046573
Diagnostics (Basel). 2021 Oct 01;11(10):
pubmed: 34679517
JAMA. 2021 May 25;325(20):2115-2116
pubmed: 33830171